Q-omics provides the consensus-scored SLC35D3 profile across patient tissues and cancer cell-line models. SLC35D3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC35D3 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, SLC35D3 RNA expression shows 12,636 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where SLC35D3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35D3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35D3 survival associations across molecular data types. SLC35D3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35D3 RNA expression–survival associations across cancer types. High SLC35D3 expression shows unfavorable associations in ACC, OV, BLCA and KIRP, but favorable associations in LGG and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC35D3 RNA expression.
This table summarizes SLC35D3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC35D3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35D3 shows higher tumor expression in COAD, HNSC, BRCA, UCEC, STAD and LUSC. The COAD box plot shows higher SLC35D3 RNA expression in tumor versus normal tissue (log2 FC = +2.359, t-test p < 0.001).
This table shows molecular features associated with SLC35D3 in patient tissues and cancer cell lines. In patient samples, SLC35D3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35D3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
